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license (http://creativeepigenetic dysregulation of gene expression in the brain.
Methods: We performed an epigenome-wide association study to identify differential DNA methyl-
ation associated with neuropathology in prefrontal cortex and superior temporal gyrus samples from
147 individuals, replicating our findings in two independent data sets (N 5 117 and 740).
Results: We identify elevated DNA methylation associated with neuropathology across a 48-kb re-
gion spanning 208 CpG sites within the HOXA gene cluster. A meta-analysis of the top-ranked probe
within the HOXA3 gene (cg22962123) highlighted significant hypermethylation across all three co-
horts (P 5 3.11! 10218).
Discussion: We present robust evidence for elevated DNA methylation associated with Alzheimer’s
disease neuropathology spanning the HOXA gene cluster on chromosome 7. These data add to the
growing evidence highlighting a role for epigenetic variation in Alzheimer’s disease, implicating
the HOX gene family as a target for future investigation.
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Alzheimer’s disease (AD), the most common form of de-
mentia, is a progressive neurodegenerative disorder that is
making an increasing contribution to the global burden ofimer’s Association. This is an open access article under the CC BY-NC-ND
R.G. Smith et al. / Alzheimer’s & Dementia 14 (2018) 1580-1588 1581disease as the population ages [1]. AD pathology is charac-
terized by the accumulation of amyloid-b plaques and tau
tangles, ultimately leading to neuronal cell loss. The neuro-
degeneration associated with AD is believed to start many
decades before clinical onset; during this “preclinical”
phase, the plaque and tangle loads in the brain increase until
a person-specific threshold level is reached and behavioral
changes and cognitive impairment become manifest [2–4].
At present, there are no disease-modifying treatments avail-
able, with existing medications only alleviating certain
symptoms of AD. A better understanding of the underlying
mechanisms precipitating the onset and progression of pa-
thology is required to enable the design of new, more effec-
tive medications.
Increased knowledge about the functional complexity of
the genome has led to speculation about the role of epigenetic
variation in health and disease, including for neurodegenera-
tive diseases such as AD [5]. Two epigenome-wide associa-
tion studies (EWAS) of AD [6,7] recently identified
consistent patterns of DNA methylation associated with
neuropathology. Of particular interest was replicated
evidence for cortex-specific hypermethylation at multiple
50-C-phosphate-G-30 (CpG) sites within ANK1, although dif-
ferences at a number of other loci were identified in one or
both studies [8]. One of the previously reported
neuropathology-associated differentially methylated posi-
tions (DMPs), cg22962123, is located within the HOXA
gene cluster on chromosome 7 [7]. Here, we present further
evidence to support a role for altered DNA methylation in
AD-associated neuropathology across an extensive region
spanning the HOXA gene cluster.2. Methods
2.1. Samples and subjects
Our discovery (Mount Sinai) cohort consisted of brain tis-
sue from 147 individuals obtained from the Mount Sinai Alz-
heimer’s Disease and Schizophrenia Brain Bank (http://icahn.
mssm.edu/research/labs/neuropathology-and-brain-banking).
From the 147 donors, two cortical regions (prefrontal cortex
[PFC, N 5 144] and superior temporal gyrus [STG,
N5 142])were used for the purposes of the study.All samples
were dissected by trained specialists, snap-frozen and stored at
280C. Further information about the samples is given in
Supplementary Table 1. Ethical approval for the project was
provided by theUniversity ofExeterMedical SchoolResearch
Ethics Committee under application number 14/02/041.
Genomic DNAwas isolated fromw100 mg of each dissected
brain region using a standard phenol-chloroform extraction
protocol and tested for purity and degradation before analysis.
For replication purposes,weusedpreviously publishedEWAS
data collected in two independent cohorts on the Illumina
Infinium Human Methylation 450K BeadChip (450K array):
(1) the “London” (Lunnon et al.) cohort, consisting of PFC,
STG, entorhinal cortex, cerebellum (CER), and premortemblood DNA methylation data from 117 individuals from the
Medical Research Council London Neurodegenerative Dis-
ease Brain Bank [6] and (2) the “Religious Orders Study/
Memory and Aging Project (ROS/MAP)” (De Jager et al.)
cohort, consisting of PFCDNAmethylation data from 740 in-
dividuals from theReligiousOrders Study and theRushMem-
ory andAging Project [7]. All samples were assigned a unique
code number for the experiment, which was independent of
age, gender, or diagnosis. This code was used throughout the
experiment and analysis.
2.2. Bisulfite treatment and Illumina Infinium BeadArray
Five hundred nanograms of genomic DNA was sodium
bisulfite converted using the EZ-DNA methylation kit
(Zymo Research, Orange, CA, USA), and DNA methylation
was subsequently quantified using the 450K array (Illumina,
USA) with arrays scanned using an Illumina iScan (software
version 3.3.28). Samples were processed by tissue and ran-
domized with respect to age and gender. The Illumina
450K array interrogates .485,000 probes covering 99% of
reference sequence (RefSeq) genes, with an average of 17
CpG sites per gene region (distributed across promoter,
50untranslated region, first exon, gene body, and
30untranslated regions). It covers 96% of CpG islands,
with additional coverage in island shores and their flanking
regions.
2.3. Microarray quality control and data normalization
Initial quality control of data was conducted using Ge-
nomeStudio (version 2011.1) to determine the status of
staining, extension, hybridization, target removal, sodium
bisulfite conversion, specificity, and nonpolymorphic and
negative controls. Probes previously reported to hybridize
to multiple genomic regions or containing a single-
nucleotide polymorphism at the single base extension site
were removed from subsequent analyses [9,10], in addition
to the 65 single-nucleotide polymorphisms used for sample
identification on the array (total probes removed 72,067).
For each probe, DNA methylation levels were indexed by
b values, that is, the ratio of the methylated signal divided
by the sum of the methylated and unmethylated signal (M/
[M 1 U]).
2.4. Data analysis
All computations and statistical analyses were performed
using R 3.0.2 and Bioconductor 2.13. Signal intensities were
imported into R using the methylumi package. Initial quality
control checks were performed using functions in the meth-
ylumi package to assess concordance between reported and
genotyped gender. Non-CpG single-nucleotide polymor-
phism probes on the array were also used to confirm that
both brain regions were sourced from the same individual
where expected. Data were preprocessed and quantile
normalized using the dasen function as part of the
R.G. Smith et al. / Alzheimer’s & Dementia 14 (2018) 1580-15881582wateRmelon package (wateRmelon_1.0.3) [11] within the R
statistical analysis environment and batch corrected using
the ComBat package [12]. Array data for each of the tissues
were normalized separately, and initial analyses were per-
formed separately by tissue. Full Illumina 450K array data
were available for the discovery (Mount Sinai) and London
(Lunnon et al.) cohorts, and thus we were able to estimate
neuronal proportions in the data using the R package
CETS [13]. For the ROS/MAP (De Jager et al.) cohort, we
only had Illumina 450K array data for probes in the HOXA
region and thus could not calculate neuronal proportions.
Therefore, the effects of age, gender, and cell type composi-
tion were regressed out of the discovery (Mount Sinai) and
London (Lunnon et al.) cohorts, whereas the effects of age
and gender only were regressed out of the ROS/MAP (De Ja-
ger et al.) cohort before subsequent analysis. For identifica-
tion of DMPs specifically altered with respect to
neuropathological measures of AD, we performed a quanti-
tative analysis in which samples were analyzed separately in
each brain region using linear regression models with
respect to Braak stage, with probes ranked according to
P values. The genic location of identified DMPs was anno-
tated by GREATannotation [14]. We have previously estab-
lished the multiple testing threshold (experiment-wide
significance) for EWAS data generated on the Illumina
450K array as P, 2.2! 1027 [15]. In brief, in this previous
study, 5000 permutations were performed repeating a linear
regression model for randomly selected groups of cases and
controls (N5 675). For each permutation, P values from the
EWAS were saved and the minimum identified. Across all
permutations, the fifth percentile was calculated to generate
the 5% of a significance threshold, which was deemed to be
P , 2.2 ! 1027. To identify differentially methylated re-Table 1
The 10 DMPs associated with Braak stage in the PFC in the discovery (Mount Sin
shown, with annotation to chromosomal location (hg19), up/downstream genes (fro
corrected DNA methylation difference (D) from Braak score 0–VI (as a %). Also
same cohort, and the matched brain regions (PFC, STG) in the London (Lunnon et






cg22867816 4:16081205 PROM1 FGFBP2 (2116347) PROM1 (1411
cg06977285 7:18127468 HDAC9 (2408457) PRPS1L1 (2599
cg05783384 2:218843735 RUFY4 (290242) TNS1 (2348
cg07349815 3:123751269 CCDC14 (270706) KALRN (2622
cg21806242 11:72532891 ATG16L2 ATG16L2 (17539) FCHSD2 (1320
cg03834767 7:90794392 CDK14 FZD1 (299390) CDK14 (1455
cg13935577 12:107974897 BTBD11 PWP1 (2104611) BTBD11 (1262
cg27078890 11:128457459 ETS1 ETS1 (223)
cg22962123 7:27153605 HOXA3 HOXA2 (211176) HOXA3 (1560
cg26199857 12:54764265 ZNF385A GPR84 (25995) ZNF385A (120,
Abbreviations: DMP, differentially methylated position; PFC, prefrontal cortexgions (DMRs), we identified spatially correlated P values
in our data using the Python module comb-p to group 3
spatially correlated CpGs in a 500-bp sliding window [16].
The coMET package was used to identify regional comethy-
lation patterns and regional EWAS results [17]. Fisher’s
combined P value analysis was performed in the MetaDE
package [18], andmeta-analysis on correlation and case con-
trol status was performed with the meta package [19] within
R [20]. Data are available for the discovery (Mount Sinai)
cohort within Gene Expression Omnibus under accession
number GSE80970. The discovery (Mount Sinai) EWAS
data set has been previously used to validate the top 100
DMPs nominated in a previously published EWAS [6]. As
such, we have not sought to replicate these top 100 DMPs
in the present study.3. Results
3.1. Hypermethylation associated with AD
neuropathology is observed in a region spanning 48 kb
across the HOXA gene cluster in the human cortex
Our primary analyses focused on matched PFC and STG
tissues from 147 individuals (Supplementary Table 1). We
used the 450K array to first quantify DNA methylation in
the PFC and identify DMPs associated with the Braak score,
a standardized measure of neurofibrillary tangle burden deter-
mined at autopsy, controlling for age, gender, and estimated
neuronal cell proportion. We identified 10 experiment-wide
significant (P , 2.2! 1027) DMPs (Table 1 and Fig. 1A),
with 78 DMPs associated with Braak stage at a more relaxed
threshold ofP, 1! 1025 (Supplementary Table 2). Of these
78 DMPs, nine were located in the HOXA gene cluster onai) cohort that reached experiment-wide significance (P, 2.2! 1027) are
mGREATannotation), P value from our quantitative association model, and
shown is the corresponding information in the matched STG samples in the
al.) cohort, demonstrating a nominally significant difference. A list of the 78
Supplementary Table 2
Discovery (Mount Sinai) cohort London (Lunnon et al.) cohort
Association with Braak stage Association with Braak stage
PFC STG PFC STG
D P value D P value D P value D P value
8) 23.90 9.80E–09 22.04 5.21E–03 - - - -
83) 3.66 2.02E–08 2.68 1.84E–04 - - 1.88 7.65E–03
85) 7.42 4.46E–08 5.55 8.01E–05 3.26 7.76E–03 3.83 6.48E–04
58) 5.15 6.70E–08 - - 2.15 .02 1.83 7.35E–03
414) 8.51 7.02E–08 5.55 4.08E–04 5.22 3.86E–04 4.62 1.10E–03
681) 24.50 8.13E–08 - - - - - -
708) 9.11 8.45E–08 5.27 1.49E–03 4.02 5.10E–03 3.73 .02
4.85 9.86E–08 - - 2.09 .02 - -
8) 7.88 1.20E–07 5.12 2.78E–04 5.62 2.24E–05 5.18 5.21E–04
816) 5.43 1.87E–07 4.44 1.02E–03 2.62 .03 - -
; STG, superior temporal gyrus.
Fig. 1. HOXA3 hypermethylation is associated with neuropathological measures of AD in cortex. (A) A Manhattan plot of association between DNA methyl-
ation in the PFC with Braak stage highlights associations at loci across the genome, with a region on chromosome 7 in the HOXA3 gene showing the greatest
number of probes associated with pathology. The red line indicates experiment-wide significance threshold (P5 2.2! 1027), with the green line indicating a
more relaxed significance threshold (P5 1! 1025). (B) Using a sliding window approach to identify differentially methylated regions, we identified six within
the HOXA gene cluster (Table 2), with the most significant region spanning 364 bp in the HOXA3 gene and containing seven CpG sites that showed increased
methylation in late-stage AD (Braak stage VI) compared to healthy controls (Braak stage 0). (C) A mini-Manhattan plot across the HOXA gene cluster. High-
lighted between gray dashed lines is a 48,754-bp region containing 208 probes characterized by neuropathology-associated hypermethylation. Red circles indi-
cate increased DNAmethylation in disease (1% between Braak 0 and Braak VI), green circles indicate decreased DNAmethylation in disease (1% between
Braak 0 and Braak VI), and black circles indicate DNA methylation differences,1% between Braak 0 and Braak VI. (D) The site demonstrating the greatest
DNA methylation difference (cg22962123) in the PFC (R 5 0.36, P 5 1.2 ! 1027) also showed a similar but weaker association in the STG (R 5 0.28,
P 5 2.78! 1024). (E) A quadrant plot of the effect size of the 208 probes identified in the PFC and their corresponding effect size in the STG highlights
a significant correlation between brain regions (R5 0.76, P5 2.66! 10240). Abbreviations: AD, Alzheimer’s disease; CpG, 50-C-phosphate-G-30; PFC, pre-
frontal cortex; STG, superior temporal gyrus.
R.G. Smith et al. / Alzheimer’s & Dementia 14 (2018) 1580-1588 1583chromosome 7, most notably in the vicinity of HOXA3, with
one HOXA DMP reaching experiment-wide significance
(cg22962123: P5 1.2! 1027). We next used a sliding win-
dow approach (comb-p [16]) to identify spatially correlated re-
gions of differential DNA methylation associated with
neuropathology; Table 2 lists DMRs spanning at least three
probes with a window size of 500 bp and a Sidak-correctedP value, .05. We identified six closely located DMRs within
the HOXA gene region, with the most significant DMR in the
HOXA region spanning seven probes in a 364-bp regionwithin
intron 1 of HOXA3 (Fig. 1B; Sidak-corrected
P5 1.19! 1029). Of note, we observed an extended region
of neuropathology-associated hypermethylation spanning
48,754 bp from upstream of the HOXA2 gene to the HOXA6
Fig. 1. Continued
R.G. Smith et al. / Alzheimer’s & Dementia 14 (2018) 1580-15881584gene and covering 208 Illumina 450K array probes (Fig. 1C).
Given that DNAmethylation at nearby CpG sites can be high-
ly correlated [21], we visualized comethylation patterns be-
tween CpG sites within HOXA3 using coMET [17] and
observed highly correlated patterns of DNA methylation be-
tween CpG sites in this extended region (Supplementary
Fig. 1). We next sought to test whether neuropathology-
associated DNA methylation patterns across this 48,754-bp
regionwere specific to the PFC, using the Illumina 450K array
to profile STG samples from the same individuals. In total,
seven probes in the region demonstrated significantly
increased DNA methylation after correcting for 208 tests
(P, 2.4! 1024), with the top PFC DMP (cg22962123) be-
ing similarly hypermethylated with respect to Braak stage(Fig. 1D; PFC: R 5 0.36, P 5 1.2 ! 1027; STG:
R5 0.28, P5 2.78! 1024). There was an overall consistent
pattern of effect sizes across both brain regions for the 208
probes in the HOXA neuropathology-associated region
(Fig. 1E; R 5 0.76, P 5 2.66! 10240).3.2. Cortical neuropathology-associated
hypermethylation in HOXA3 is observed in independent
study cohorts
We next sought to replicate the observation of
neuropathology-associated hypermethylation across these
208 probes in two independent, previously published data
sets. First, we examined the “London” (Lunnon et al. [6])
Table 2
DMRs associatedwith Braak stage in the PFC—Shown are all significantly associated regions (Sidak-corrected P value, .05) that contain three or more probes,
with chromosomal location (hg19), up/downstream genes, number of probes in the significant region, and Sidak-corrected P value





Chr11 2,321,770 2,323,247 C11ORF21 TSPAN32 (2734) C11orf21 (1634) 27 3.20E–11
Chr7 27,153,580 27,153,944 HOXA3 HOXA2 (211332) HOXA3 (15452) 7 1.19E–09
Chr7 27,154,262 27,155,234 HOXA3 HOXA2 (212318) HOXA3 (14466) 16 4.31E–09
Chr7 27,169,957 27,171,401 HOXA4 HOXA4 (2261) 21 2.13E–08
Chr11 3,15,908 3,16,456 IFITM1 Closest IFITM1 (12329) IFITM3 (14868) 5 4.02E–08
Chr12 58,119,915 58,120,237 AGAP2 AGAP2 (111,953) OS9 (132,172) 6 1.22E–07
Chr7 27,183,133 27,184,853 HOXA5/HOXA-AS3 HOXA5 (2706) 42 2.19E–06
Chr5 78,985,425 78,985,900 CMYA5 CMYA5 (237) 10 2.31E–06
Chr19 10,736,006 10,736,448 SLC44A2 SLC44A2 (1293) 8 3.68E–06
Chr19 39,086,733 39,087,186 MAP4K1 MAP4K1 (121,604) RYR1 (1162490) 4 4.94E–06
Chr6 10,556,147 10,556,523 GCNT2 GCNT6 (277,658) GCNT2 (127,746) 3 2.93E–05
Chr3 194,014,592 194,015,171 GRM2 Closest CPN2 (157,175) HES1 (1160,948) 4 3.24E–05
Chr4 184,908,351 184,909,018 STOX2 STOX2 (182,176) ENPP6 (1230,429) 8 3.60E–05
Chr7 27,145,972 27,146,445 HOXA3 HOXA2 (23779) 5 4.11E–05
Chr17 46,388,390 46,388,465 SKAP1 SKAP1 (1119,124) SNX11 (1203,508) 3 4.77E–05
Chr17 74,475,240 74,475,402 RHBDF2 RHBDF2 (122,168) AANAT (125,888) 5 8.13E–05
Chr3 51,740,741 51,741,280 GRM2 GRM2 (275) 6 1.93E–04
Chr17 41,363,502 41,364,121 NBR1/TMEM106A TMEM106 A (282) 11 3.04E–04
Chr17 43,318,610 43,319,371 FMNL1 FMNL1 (119,835) SPATA32 (120,488) 6 4.51E–04
Chr7 158,281,410 158,281,613 PTPRN2 PTPRN2 (198,859) 3 4.66E–04
Chr13 43,565,901 43,566,496 EPSTI1 DNAJC15 (231,140) TNFSF11 (1417,910) 9 4.72E–04
Chr20 57,582,787 57,583,520 CTSZ Closest CTSZ (2852) 18 6.82E–04
Chr19 3,179,545 3,180,035 S1PR4 NCLN (25808) S1PR4 (11054) 4 7.59E–04
Chr22 37,608,611 37,608,819 SSTR3 Closest SSTR3 (2353) 3 8.84E–04
Chr13 113,698,408 113,699,016 MCF2L F7 (261,409) MCF2L (175,177) 13 9.15E–04
Chr9 34,457,129 34,457,500 FAM219A DNAI1 (21518) 4 1.05E–03
Chr17 75,315,081 75,315,567 SEPT9 TNRC6C (2685,813) SEPT9 (137,832) 8 1.28E–03
Chr16 29,674,618 29,675,214 SPN SPN (1336) 6 1.77E–03
Chr1 55,246,867 55,247,408 TTC22 PARS2 (216,951) DHCR24 (1105,753) 5 2.45E–03
Chr12 58,132,558 58,133,008 AGAP2 (2754) 3 3.00E–03
Chr7 27,138,712 27,138,974 HOTAIRM1 HOXA1 (23250) 4 3.19E–03
Chr16 67,686,832 67,687,392 RLTRP ACD (17534) RLTPR (18290) 4 3.59E–03
Chr12 58,129,855 58,130,410 AGAP2 AGAP2 (11896) OS9 (142,229) 4 4.42E–03
Chr17 19,314,299 19,314,618 RNF112 RNF112 (248) 6 9.80E–03
Chr15 40,583,227 40,583,422 PLCB2 PLCB2 (116,798) PAK6 (151,704) 3 .01922
Chr15 38,988,533 38,988,860 C15ORF53 THBS1 (2884,597) RASGRP1 (2131,690) 4 .01974
Chr16 1,482,952 1,483,192 CCDC154 Closest C16orf91 (23727) 3 .02843
Abbreviations: DMR, differentially methylated region; PFC, prefrontal cortex.
R.G. Smith et al. / Alzheimer’s & Dementia 14 (2018) 1580-1588 1585data set, comprising Illumina 450K array data generated us-
ing matched PFC, STG, entorhinal cortex, CER, and
premortem blood samples obtained from 117 donors
(described in [6]; Supplementary Table 1). We observed a
similar pattern of Braak-associated DNAmethylation across
this 208-probe region in the replication cohort in both the
PFC (Fig. 2A) and STG (Supplementary Fig. 2), with a high-
ly correlated effect size between cohorts in both brain re-
gions (PFC: Fig. 2B; R 5 0.74, P 5 2.27 ! 10237; STG:
Supplementary Fig. 3; R 5 0.68, P 5 1.87 ! 10229)—15
probes in the PFC and 6 probes in the STG reaching our cor-
rected significance threshold (P, 2.4! 1024). In contrast,
no probes in this region reached the corrected significance
threshold in the entorhinal cortex (Supplementary Fig. 4),
although the effect size was still correlated (R 5 0.41,
P 5 1.23! 1029). Similarly, no probes reached the signif-icance threshold in the CER (Supplementary Fig. 5) or in
premortem whole blood collected in a subset (N 5 57) of
the same individuals (Supplementary Fig. 6), with no corre-
lation of effect sizes in either the CER (R5 0.03, P5 .639)
or blood (R 5 0.11, P 5 .138). This indicates that the
association may be specific to only particular regions of
the cortex.
We subsequently assessed this region in the “ROS/MAP”
(De Jager et al.) data set comprising of 740 PFC samples pro-
filed on the Illumina 450K array (as described in De Jager et
al. [7]; Supplementary Table 1) observing a similar pattern of
effects with highly significant neuropathology-associated
hypermethylation across probes in the HOXA genic region
(Fig. 2C), and a significant correlation of effect size with
the same 208 probes in the PFC in the discovery cohort
(Fig. 2D; R5 0.80,P5 2.39! 10248). A Fisher’s combined
Fig. 2. Replication of neuropathology-associated DNA methylation differences across the HOXA gene cluster in additional study cohorts. (A) We identified a
consistent pattern of increased DNAmethylation across theHOXA cluster in the London (Lunnon et al.) cohort in the PFC (B) with a strong correlation in effect
size across the 208 probes in the region between data sets (R5 0.74, P5 2.24! 10237). (C) A similar pattern of DNAmethylation changes was observed in the
PFC in the ROS/MAP (De Jager et al.) cohort, (D) with a strong correlation in effect size across the 208 probes in the region between data sets (R 5 0.80,
P 5 2.39! 10248). (E) A Fisher’s combined P value meta-analysis of the PFC with respect to Braak stage across all three cohorts showed striking patterns
of increasedDNAmethylationwithmany probes in theHOXA3 region reaching experiment-wide significance. (F) Themost significant probe identified from the
discovery cohort (cg22962123) was also the most significant probe in the meta-analysis (P5 3.11! 10218) and characterized by neuropathology-associated
hypermethylation across all three cohorts. In plots (A) and (C) red circles indicate increased DNAmethylation in disease (1% between Braak 0 and Braak VI),
green circles indicate decreased DNA methylation in disease (1% between Braak 0 and Braak VI), and black circles indicate DNA methylation differences
,1% between Braak 0 and Braak VI. In plots (A), (C), and (E), the red line indicates experiment-wide significance (P 5 2.2! 1027), whereas the blue line
indicates significance after correcting for 208 tests (P5 2.4! 1024). In plots (A), (C), and (E), the gray dashed lines indicate the same region across the graphs
for reference. These show the probes in the extended DMR. In plot (F), red denotes the PFC and green denotes the STG. Abbreviations: DMR, differentially
methylated region; PFC, prefrontal cortex; ROS/MAP, Religious Orders Study/Memory and Aging Project; STG, superior temporal gyrus.
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R.G. Smith et al. / Alzheimer’s & Dementia 14 (2018) 1580-1588 1587P value of DNA methylation differences across this region in
all three PFC data sets confirmed a clearly defined region of
significant neuropathology-associated elevated DNAmethyl-
ation, with many individual DMPs passing the threshold for
experiment-wide significance (Fig. 2E), and a consistent
pattern of effects across the three cohorts (Supplementary
Fig. 7). The most significant DMP identified within the
HOXA3 gene in our discovery cohort (cg22962123;
Table 1) was also the most significant DMP in our Fisher’s
combined P value analysis (P 5 1 ! 10220). A meta-
analysis comparing Braak 0 to VI demonstrated increased
DNA methylation with respect to Braak stage across all co-
horts in the PFC (Fig. 2F; P 5 3.11 ! 10218). Together,
our data suggest that DNA hypermethylation across the
extended HOXA gene region is robustly associated with
AD-related neuropathology in both the PFC and STG, with
the strongest effects in the vicinity of HOXA3.4. Discussion
We identified an extended region of elevated DNA
methylation in the HOXA gene cluster that is associated
with AD neuropathology, with consistent effects seen
across three independent postmortem brain sample cohorts.
Although one previous study had demonstrated differential
methylation at a single CpG within the HOXA gene cluster
[7] and another identified a DMR spanning seven CpG sites
[6], this represents the first study to illustrate that hyperme-
thylation in this region extends to 208 DMPs, spanning
approximately 48.7 Kb. Differential DNA methylation in
the HOXA gene cluster has been previously reported in
blood collected from Down syndrome individuals [22],
which is interesting given that many Down syndrome indi-
viduals develop AD resulting from an additional copy of
the APP gene due to trisomy on chromosome 21. The
Down syndrome study demonstrated differential DNA
methylation in 20 probes largely located within HOXA2.
Of note, 17 of these probes were significantly hypermethy-
lated in the PFC in our discovery (Mount Sinai) cohort.
However, none were differentially methylated in premor-
tem blood in the London (Lunnon et al.) cohort. In the
context of other neurodegenerative disorders, one study
that investigated microRNAs targeting HOX genes in Hun-
tington’s disease demonstrated increased levels of micro-
RNAs related to HOXA5, HOXA10, HOXA11, HOXA-
11AS, HOXA13, and HOTAIRM1 in the PFC in Hunting-
ton’s disease [23]. Although HOX genes encode potent
transcription factors that play a critical role in embryonic
development [24], a recent study in Drosophila also high-
lighted a potent protective function for HOX genes in neu-
rons, implicating a role in neuroprotection [25].
Interestingly, this study also highlighted how HOX genes
act to maintain expression of the ankyrin locus, an impor-
tant observation given our previous finding of altered DNA
methylation in ANK1 in AD [6]. Indeed, to further explorethis hypothesis, we examined the correlation between DNA
methylation levels at the most significant HOX probe iden-
tified in the present study (cg22962123) with the two
ANK1 DMPs that we previously identified to be associated
with AD neuropathology (cg11823178 and cg05066959)
[6,7] in the PFC, identifying a significant correlation with
both ANK1 probes (cg11823178: R 5 0.24,
P 5 5.15 ! 10210; cg05066959: R 5 0.20,
P 5 2.93 ! 1028). Although this correlation could
reflect the association between both HOXA3 and ANK1
probes with Braak stage, it could highlight a novel
physiological mechanism, particularly as we still
observed significant hypermethylation (P 5 1.67
! 1025) at our top HOXA probe (cg22962123), when
controlling for levels of DNA methylation in the top
ANK1 probe (cg11823178). Looking to the future,
analyses of gene expression levels should be performed
to facilitate the interpretation of the DNA methylation
differences we observe in HOXA. To conclude, this study
provides further evidence for altered epigenetic processes
in the pathophysiology of AD and suggests that further
work on the neuroprotective functions of HOX genes is
warranted.Acknowledgments
This work was funded by NIH grant R01 AG036039 to
J.M. and by Alzheimer’s Society grant AS-PG-14-038,
Alzheimer’s Association grant NIRG-14-320878, and a
grant from BRACE (Bristol Research into Alzheimer’s
and Care of the Elderly) to K.L. Brain banking and neuro-
pathology assessments for the discovery cohort from the
Mount Sinai Alzheimer’s disease and Schizophrenia
Brain Bank were supported by NIH grants AG02219,
AG05138, and MH064673 and the Department of Veter-
ans Affairs VISN3 MIRECC. Brain banking and neuro-
pathological assessment for the London (Lunnon et al.)
cohort was provided by The London Neurodegenerative
Diseases Brain Bank, which receives funding from the
Medical Research Council (MRC) and as part of the
Brains for Dementia Research (BDR) programme, jointly
funded by Alzheimer’s Research UK and Alzheimer’s So-
ciety. The ROS/MAP (De Jager et al.) cohort was sup-
ported by the National Institutes of Health grants: R01
AG036042, R01AG036836, R01 AG17917, R01
AG15819, R01 AG032990, R01 AG18023, RC2
AG036547, P30 AG10161, P50 AG016574, U01
ES017155, KL2 RR024151, and K25 AG041906-01.Supplementary data
Supplementary data related to this article can be found at
https://doi.org/10.1016/j.jalz.2018.01.017.
R.G. Smith et al. / Alzheimer’s & Dementia 14 (2018) 1580-15881588RESEARCH IN CONTEXT
1. Systematic review: We performed an epigenome-
wide association study (EWAS) to identify differen-
tial DNA methylation associated with Braak stage in
a discovery cohort of 147 individuals. A regional
analysis identified six differentially methylated re-
gions (DMRs), consisting of.3 differentially meth-
ylated positions (DMPs) with a Sidak-corrected P
value ,0.05, within the HOXA gene cluster. Further
investigation highlighted a region of neuropa-
thology-associated hypermethylation spanning
.48kb (208 probes) across the HOXA gene cluster.
2. Interpretation: HOX genes encode transcription fac-
tors important in neural development. A recent study
has provided evidence that Hox genes can maintain
expression of the Ank locus [25], which is particu-
larly interesting given that two previous EWAS have
provided robust evidence for differential DNA
methylation in AD cortex in the ANK1 gene [6,7].
A significant correlation of DNA methylation was
seen between the most significant HOX probe
identified in the current study with the two ANK1
DMPs previously identified [6,7], even when
controlling for levels of DNA methylation in ANK1.
3. Future directions: Analyses of gene expression levels
should be performed to facilitate the interpretation of
the DNA methylation differences we observed in
HOXA as well as determining whether these DNA
methylation changes are a cause or consequence of
AD neuropathology.References
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